Tagged with generics

Switzerland With over seven decades of innovation behind it, Lupin has evolved from an Indian pioneer in anti-tuberculosis therapies into a global pharmaceutical leader shaping the future of complex generics, speciality care, and biosimilars. As the company accelerates its European expansion, Laurent Renaudie shares how Lupin’s entrepreneurial culture, patient-centred mission, and…

Denmark Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. And with life science exports surpassing EUR 23 billion last year…

Switzerland Eight years after establishing its Swiss affiliate as a one-man operation, Accord Healthcare has built a strong position in one of Europe’s most competitive markets, with a focused strategy in oncology, rheumatology, and neurology. In this interview, Country Director and General Manager Richard Hummel reflects on the affiliate’s rapid growth,…

USA John Murphy, President and CEO of the Association for Accessible Medicines (AAM), outlines a compelling vision for improving access to high-quality, affordable medicines in the US. He stresses that by directing greater focus to the generic and biosimilar market, tackling structural challenges, safeguarding supply chains, and enabling strategic domestic investment,…

France The top 10 companies in the French retail generics market for 2024 according to Smart Pharma Consulting’s insights on the French pharma market. Last year, Viatris and Biogaran generated more than EUR 2.9 billion in sales and, taken together, represented over half of the total French retail generic market in…

Europe For over two decades, Europe’s pharmaceutical manufacturing footprint has steadily shifted offshore towards countries like China and India, driven by the pursuit of lower costs and operational efficiencies. However, the COVID-19 pandemic, coupled with growing geopolitical instability and increasing complexity in modern therapies, has exposed the risks of this model.…

Switzerland Alexander Salzmann with nearly a decade at Sandoz, reflects on the company’s transition from a Novartis division to an independent, Swiss-listed entity. In this interview, Salzmann discusses the challenges and opportunities of operating a business in the company’s home market Switzerland, and the Sandoz ambition to lead the generics and…

Switzerland Currently supplying high-quality medicines to approximately 1 billion patients around the world annually, few pharmaceutical companies straddle both scale and innovation as deliberately as Viatris. In Switzerland – a market perceived as small in scale, yet rich in complexity – the company is redefining its role, identifying where it can…

Denmark Peter Jorgensen, Director of the Danish Generic and Biosimilar Medicines Industry Association, discusses Denmark’s robust framework for generics and biosimilars, offering insight into a system that has delivered high penetration, cost savings, and broad public trust. From legal structures and patient attitudes to incentives and hospital adoption, Jorgensen outlines why…

Switzerland With the pharmaceutical landscape growing increasingly complex, few mid-sized players manage to carve out a distinct, resilient path. Rivopharm, a Swiss-headquartered generics manufacturer, is doing just that, expanding its direct presence across Europe, targeting technically demanding niche products, and balancing growth with operational precision. In this interview, CEO Piero Poli…

Saudi Arabia Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare payer in the country and, with medicines already consuming over 20 percent of national healthcare spending, is putting increasing emphasis…

Saudi Arabia Cooper Pharma, with its 90-year legacy, is at the forefront of transforming the pharmaceutical landscape in the Middle East. From localizing production in Saudi Arabia to pioneering collaborations with global institutions, the company is driving innovation in a rapidly evolving market. As Saudi Arabia’s Vision 2030 reshapes the future of…